What ROAD2H means for policymakers and payers (health insurers)

ROAD2H will model key decision points within the disease pathways for COPD and CKD, incorporating cost-effectiveness considerations as well as broader, non-financial policy and other constraints. Whereas health technology assessment (HTA) traditionally compares the relative cost-effectiveness of two individual interventions (e.g. smoking cessation versus a specific drug for COPD), ROAD2H could be seen as a “macro HTA”, whereby efficiency and quality are being optimized at various critical decision points for the given disease.

Since ROAD2H will provide optimised clinical decision support and collect realtime data on actual clinical decisions taken, clinicians will also be to required to record and justify deviations from the recommended course of action. Thus ROAD2H will provide a transparent way for policymakers and payers to monitor and benchmark healthcare provider and clinician performance against evidence-informed quality standards, ensuring that healthcare delivery is efficient and produces the greatest benefit for citizens.